Omega-3 fatty acids have antidepressant activity in forced swimming test in Wistar rats

Acta Poloniae Pharmaceutica - Drug Research

Volumn 64, Issue 3, 2007, Pages 271-276

  Lakhwani, Lalit ^a   Tongia, Sudheer K ^a   Pal, Veerendra S ^a   Agrawal, Rajendra P ^a   Nyati, Prem ^a   Phadnis, Pradeep ^a  

^a MGM MEDICAL COLLEGE   (India)

Author keywords

Depression; Fluoxetine; Forced swimming test; Immobility; Omega 3 fatty acids; Swimming

Indexed keywords

DOCOSAHEXAENOIC ACID; FLUOXETINE; ICOSAPENTAENOIC ACID; ANTIDEPRESSANT AGENT; OMEGA 3 FATTY ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG STRUCTURE; FORCED SWIMMING TEST; IMMOBILIZATION; NONHUMAN; RAT; WISTAR RAT; ANALYSIS OF VARIANCE; ANIMAL; ANIMAL BEHAVIOR; COMPARATIVE STUDY; DISEASE MODEL; DRUG ADMINISTRATION; MALE; SWIMMING;

ANALYSIS OF VARIANCE; ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; DEPRESSION; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; FATTY ACIDS, OMEGA-3; FLUOXETINE; MALE; RATS; RATS, WISTAR; SWIMMING;

EID: 34548423681     PISSN: 00016837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV, 4th ed., Washington D.C. 2000.
2. th edn. Sadock B. J. Sadock V. A. Eds., pp. 1298-1308, Lippincott Williams & Wilkins, Philadelphia 2000.
3. Klerman G. L.: Br. J. Psychiatry 152, 4 (1988).
4. Klerman G. L., Weissman M. M.: JAMA 261, 2229 (1989).
5. Hibbeln J. R.: Lancet 35, 11213 (1998).
6. Tanskanen A., Hibbeln J. R., Hintikka J. et al.: Arch. Gen. Psychiatry 58, 512 (2001).
7. Porsolt R. D.: Behavioral despair. in Antidepressants: neurochemical, behavioral, and clinical perspectives. Enna S. J. Ed. p. 121, Raven Press, New York 1981.
8. Porsolt R. D.: Behavioral despair: present status and future perspectives. in Antidepressants: thirty years on. Leonard B. E., Spencer P. J. Eds., p. 85, CNS Publishers, London 1990.
9. Porsolt R. D., Lenegre A.: Behavioral models of depression, in Experimental approaches to anxiety and depression, Elliot J. M., Heal D. J., Marsden C. A. Eds., p. 73, Wiley, New York 1992.
10. Porsolt R., Le Pichon M., Jalfre M.: Nature 266, 730 (1977).
11. Porsolt R. D., Anton G., Deniel M., Jalfre M.: Eur. J. Pharmacol. 47, 379 (1978).
12. Porsolt R. D., Berlin A., Blavet N., Deniel M., Jalfre M.: Eur. J. Pharmacol. 57, 201 (1979).
13. Porsolt R. D., Lenegre A., McArthur R. A.: Pharmacological models of depression. in Animal models in psychopharmacology, Olivier B., J. Slangen J. J. Mos J. Eds., p. 137, Birkhauser, Basel 1991.
14. Detke M. J., Rickels M.. Lucki I.: Psychopharmacology 121, 66 (1995).
15. Goodman and Gilman: The Pharmacological Basis of Therapeutics, 11th ed., p. 441, McGraw Hill, New York 2006.
16. Carlezon W.A., Mague S. D., Parow A. M., et al.: Biol Psychiatry 57, 343 (2005).
17. Suarez E. C., Krishnan R. R., Lewis J. G.: Psychosom. Med. 65, 362 (2003).
18. James M. J., Gibson R. A., Cleland L. G.: Am. J. Clin. Nutr. 71, 343S (2000).
19. Ishihara K., Murata M., Kaneniwa M., et al.: Lipids 33, 1107 (1998).
20. Kuwamori M., Wada M., Takita T., et al.: Biosci. Biotechnol. Biochem. 61, 763 (1997).
21. Sapolsky R. M.: Biol. Psychiatry 48, 755 (2000).
22. Rajkowska G., Miguel-Hidalgo J. J., Wei J., et al.: Biol. Psychiatry 45, 1085 (1999).
23. Ikemoto A., Nitta A., Furukawa S., et al.: Neurosci. Lett. 285, 99 (2000).
24. Ikemoto A., Kobayashi T., Watanabe S., Okuyama H.: Neurochem. Res. 22, 671 (1997).
25. Nestler E. J, Barrot M., DiLeone R. J., et al.: Neuron 34, 13 (2002).
26. Shimizu E., Hashimoto K., Okamura N., et al.: Biol. Psychiatry 54, 70 (2003).
27. Molteni R., Barnard R. J., Ying Z., et al.: Neuroscience 112, 803 (2002).
28. Williard D. E., Harmon S. D., Kaduce T. L., et al.: J. Lipid Res. 42, 1368 (2001).
29. Wu A., Molteni R., Ying Z., Gomez-Pinilla F.: Neuroscience 119, 365 (2003).
30. Russo-Neustadt A.: Semin. Clin. Neuropsychiatry 8, 109 (2003).
31. Bourre J. M., Dumont O., Piciotti M., et al.: World Rev. Nutr. Diet 66, 103 (1991).
32. Brenner R. R.: Prog. Lipid Res. 23, 69 (1984).
33. Spector A. A., Yorek M. A.: J. Lipid Res. 26, 1015 (1985).
34. Yehuda S., Rabinovitz S., Carasso R. L., Mostofsky D. I.: Peptides 19, 407 (1998).
35. Bourre J. M., Bonneil M., Clement M., et al.: Prostaglandins Leukot. Essent. Fatty Acids 48, 5 (1993).
36. Fernstrom J. D.: Lipids 34, 161 (1999).
37. Heron D. S., Shinitzky M., Hershkowitz M., Samuel D.: Proc. Natl. Acad. Sci. USA 77, 7463 (1980).
38. Haag M.: The Medicine Journal (SA) 43, 13 (2001).
39. Van Rooyen J. M., Offermeier J., Stahmer S. D.: The Medicine Journal (SA) 33, 3 (1991).
40. Garcia-Sanz J.A., Vazquez-Prado J., Villalobos-Molina R.: Arch. Med. Res. 30, 449 (1999).
41. Popoli M., Brunello N., Perez J., Racagni G.: J. Neurochem. 74, 21 (2000).
42. Murphy M. G.: Biochem. Biophys. Res. Commun. 132, 757 (1985).
43. Nicolas C., Lacasa D., Guidicelli Y., et al.: J. Nutr. 121, 1179 (1991).
44. Ener R. A., Meglathery S. B., Van Decker W. A.: Pain Med. 4, 63 (2003).